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Malignant hyperthermia is a pharmacogenic disease and is manifest by a
hypermetabolic crisiswithtachycardia, ventricular ectopy, metabolic acidosis,
and a rapid rise in body temperature. "Ecstasy", 3,4-methylenedioxy-
methamphetamine (MDMA), is a semisynthetic amphetamine, the recreational
use of which has increased in recent years. Severe reactions to MDMA have
been noted in the past, including hyperthermia, rhabdomyolysis and
disseminated intravascular coagulation 1. Reports ofoverdose with MDMA are
rare, but hyperthermia and rhabdomyolysis have been reported in
association 23,4. Compounds such asMDMAarethoughttocausehyperthermia
by a central action at 5HT2 receptors 5. However dantrolene, a muscle relaxant
acting peripherally, has been used apparently successfully in the treatment of
MDMA overdose 4. We report a case of acute perioperative increase in
temperature, initially diagnosed and treated as malignant hyperpyrexia, in a
patient who later emerged to be an "ecstasy" abuser.
CASE REPORT
A 23 year old man was scheduled for internal fixation of a two day old fracture
- dislocation ofthe right ankle. He had suffered no other injury. He had a squint
correction when 6 years old and repair of a Mallory-Weiss tear when aged 17.
Both anaesthetics were uneventful, employing thiopentone, suxamethonium,
pancuronium andhalothane. Hereportednomedicationsorallergies, consumed
10-20 units ofalcohol perweek and was a moderate smoker. He was apyrexial,
and othervital signs were normal. Physical examination was unremarkable. He
was premedicated with temazeparn 20 mg.
On arrival inthe anaesthetic room ECG, pulse oximeter and non-invasive blood
pressure monitors were applied. An 18 sw gauge intravenous cannula was
placed in a vein on the dorsum of the left hand and an intravenous infusion of
Hartmann's solution was commenced. Anaesthesia was induced with fentanyl
0.1mg and propofol 150 mg. Afterinduction, a size4 laryngeal mask (Intavent)
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was inserted and anaesthesia was maintained with 66% nitrous oxide in oxygen
and isoflurane 0.5-1.5%, by spontaneous respiration through a Bain breathing
system. The patient was moved to the operating theatre where the same
monitors were reapplied. A tourniquet was applied to the right thigh. No
antibiotics were administered.
Surgery proceeded uneventfully for 45 min with an SaO2 of 98% and an end-
tidal CO2 of 4.0-4.5%. It was then noticed that the patient's left shoulder was
flushed, felt warm and the heart rate increased suddenly from 55 to 90 beats/
min. At the same time there was a rapid rise in the end-tidal CO2 to 8.5%. A
nasal temperature probe was inserted which recorded a temperature of38.9°C.
The heart rate then increased to 120 beats/min. There was no cyanosis and the
pulse oximeter continued to show a saturation of 98%. Masseter spasm and
rigid upper limbs were noted. An arterial blood gas sample revealed pH 7.28,
PO2 17.2 kPa, and PCO2 8.04 kPa. A presumptive diagnosis of malignant
hyperpyrexia was made and treatment commenced.
Isoflurane administration was stopped and the patient was switched to a 'clean'
anaesthetic machine and unused Bain breathing system. While dantrolene
sodium was prepared, crushed ice and a cooling blanket were applied to the
patientandhewasspongedwithiced water. Atracheal tube and anoesophageal
temperature probe were inserted andthe patientmanually ventilated with 100%
oxygen. The temperature continued to rise to 390C. The Hartmann's solution
was replaced with 0.9% saline. A 16 gauge cannula was placed in the left
antecubital fossa and a 20 gauge cannula in the right radial artery. Dantrolene
sodium 1mg/kg, pancuronium 4 mg, midazolam 10 mg and methylprednisolone
1000mg were administered. In spite of the cooling measures the temperature
continued to rise to 39.1 °C with a tachycardia of 150 beats/min. A double
lumen central venous catheter was inserted through the right internal jugular
vein and an ice cold 0.9% saline infusion commenced. A urinary catheter was
inserted and 200ml mannitol 10%, was administered to prevent tubular
necrosis.
The patient developed severe bronchospasm which responded to 250mg
aminophylline by slow intravenous injection. The oesophageal temperature did
not rise beyond 39.20C. Repeat arterial blood gas samples at ten min. intervals
showed normal pH. Serum potassiummeasurements remained slightly raised.
Oesophageal temperature gradually decreased to 36.8°C over the next two
hours and cooling was stopped at this stage. The patient was transferred to the
intensive care unit, sedated with propofol and fentanyl infusions and ventilated
overnight. All subsequent measurements of, blood urea and electrolyte
concentrations, liver function tests, arterial blood gases and clotting status
were normal. He remained normothermic and maintained a good urine output
over the next 24 hours. All laboratory investigations remained normal. The
highestcreatine kinase reported in that time was 235 ,umol/1. The endotracheal
tube was removed the next morning and he was discharged to the orthopaedic
ward. He made a full recovery and was discharged home two days later with
instructions on follow up. The patient later confessed to regular ecstasy abuse,
the most recent episode being two days prior to the day of surgery. No relevant
personal or family history was obtained and he was referred to and examined
by a neurologist specialising in muscle disease. On his advice, confirmation of
malignant hyperpyrexia as a diagnosis was not pursued.
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DISCUSSION
Malignant hyperpyrexia is a rare, potentially fatal condition well recognised in
anaesthesia. The true incidence is unknown, with estimates ofup to 1:250,000
overall 6. The primary defect is not known, but is believed to involve an
abnormally sensitive calcium-induced calcium release mechanism. As
anaesthetists have become more aware ofthe condition the mortality rate has
fallen, but concomitantly the number of dubious and aborted cases has risen.
The commoner trigger agents are suxamethonium and halothane, but all
volatile agentshave beenimplicated7,89. Propofol has beenstudied in vitroand
in vivo and is considered safe 10. Previous uneventful anaesthesia is not an
indicator ofnonsusceptibility, even ifknown trigger agents have been used8'11.
Malignant hyperpyrexia can be classified into four categories: the fulminant
form, abortive malignant hyperpyrexia, masseter spasm and atypical
presentations. The clinical diagnosis of malignant hyperpyrexia, especially
when made early inthe course ofthe crisis, can be difficult as the signs are non-
specific at this stage and other conditions can mimic it to a certain extent.
Muscle rigidity may or may not be present, and the predictive value ofthe most
informative signs, when combined, is only 78% specific 12. Though an increase
in temperature of 1°IC/hour is quoted as one of the diagnostic criteria in
malignanthyperpyrexia, itmaywell bemuchfaster8.Anincreaseintemperature
is a relatively late sign, so capnography is of crucial importance at an early
stage 13. Hyoglobinuria and elevated serum creatine kinase are also indicative
of malignant hyperpyrexia 12.
Dantrolene, a drug which impairs calcium release from skeletal muscle
sarcoplasmic reticulum, is recommended for treatment. It has also been used
inthetreatmentofhypermetabolic statesassociatedwiththeophyllineoverdose,
the neuroleptic malignant syndrome, exertional heat-stroke, tetanus, toxic
reactions to, y-asperaginase, amphoteracin-B induced rigors and delirium
tremers 14, 15, 16. It has been employed in the treatment of massive MDMA
4 overdose
In recent years the recreational use of the semisynthetic amphetamine,
"ecstasy" has increased. Preparations ofthis substance may contain relatively
pure methylene dioxyamphetamine (MDA, "Eve") or its N-methyl cogener
MDMA, and biotransformation ofMDMA to MDA may occur 17. Clinically, MDA
has been evaluated as an anorectic and antidepressant and as an adjunct to
psychotherapy, though it has yet to find an acceptable place in the medical
pharmacopoeia 18,19. MDA has been shown to be neurotoxic, destroying
serotoninergic nerve terminals in the brain 19. These substances induce a state
ofexcitation ofthecentral nervous system, withcentral autonomichyperactivity,
manifest as changes in mood (usually euphoric, sometimes depressive) and
perception. Trismus, myalgia, tachycardia, hypertension and hyperthermia
have been reported2021. Studies in animals have shownMDAtoxicityto parallel
thatofamphetamines andtoproducemydriasis, profusesalivation, tachycardia,
hypertension, hyperthermia, convulsions anddeath 19. Thesesigns can develop
several hours after Ecstasy ingestion; the prolonged duration of
sympathomimetic action relates to the resistance of these substances to
degradation by enzymes that metabolise catecholamines 22. The unpredictable
hyperthermic response to MDA or MDMA in certain individuals may reflect an
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underlying metabolic myopathy, with deregulation of mycoplasmic calcium
ionhomeostasis 23. The mechanism may involve a combination ofdirecteffects
ofthe drugs and a raised metabolic rate, dehydration or any cause ofstress 21.
The cause ofthe sudden increase intemperature inthiscase remains uncertain.
Initially the clinical impression was of a fulminant malignant hyperpyrexia,
though the lack of progression suggested this not to be the case. It may have
been an aborted or atypical form of malignant hyperpyrexia, though in view of
the normal postoperative serum creative kinase concentration this is unlikely.
It may have been a delayed hyperthermic response to the MDMA alone, and
purely coincidental withthe hospital admission. Astheinterval betweenthe last
ingestion of "Ecstasy" and surgery was less than 48 hours it may have been a
result of a combination of residual MDMA, due to its slow metabolism, and a
combined factor of hospital admission, surgical stress, catecholamine release
and the administration of anaesthetic drugs. A MDMA-induced Ca ++ release
myopathy leading to a deregulation of mycoplasmic calcium ion homeostasis
would also be an explanation: as thefinal common pathway in the development
of malignant hyperpyrexia is excessive mycoplasmic Ca ++, and hyperthermia
with MDMA in certain individuals may reflect a deregulation of mycoplasmic
calcium ion homeostasis, this case may represent an additional type of
malignant hyperpyrexia.
The differential diagnosis of severe hyperthermia should include 3,4
methylenedioxymetamphetamine intoxication, and serum MDMA
concentrations should be measured in young adults who develop hyperthermia
during anaesthesia 21, 22. With the increasing abuse of MDMA and related
compounds, thepreoperative interrogation ofthepatientregarding recreational
drug abuse should assume greater importance.
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